X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Merck Ltd with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

MERCK LTD vs DIVIS LABORATORIES - Comparison Results

MERCK LTD    Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    MERCK LTD DIVIS LABORATORIES MERCK LTD/
DIVIS LABORATORIES
 
P/E (TTM) x 44.0 35.3 124.5% View Chart
P/BV x 6.4 6.9 93.4% View Chart
Dividend Yield % 0.5 0.7 81.0%  

Financials

 MERCK LTD   DIVIS LABORATORIES
EQUITY SHARE DATA
    MERCK LTD
Dec-17
DIVIS LABORATORIES
Mar-18
MERCK LTD/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1,3581,142 118.9%   
Low Rs933533 175.0%   
Sales per share (Unadj.) Rs665.0146.6 453.7%  
Earnings per share (Unadj.) Rs56.633.0 171.2%  
Cash flow per share (Unadj.) Rs72.538.4 188.7%  
Dividends per share (Unadj.) Rs15.0010.00 150.0%  
Dividend yield (eoy) %1.31.2 109.7%  
Book value per share (Unadj.) Rs441.7222.8 198.2%  
Shares outstanding (eoy) m16.60265.47 6.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.75.7 30.1%   
Avg P/E ratio x20.225.3 79.9%  
P/CF ratio (eoy) x15.821.8 72.5%  
Price / Book Value ratio x2.63.8 69.0%  
Dividend payout %26.530.3 87.6%   
Avg Mkt Cap Rs m19,011222,318 8.6%   
No. of employees `0001.510.8 14.3%   
Total wages/salary Rs m1,6964,561 37.2%   
Avg. sales/employee Rs Th7,150.03,616.0 197.7%   
Avg. wages/employee Rs Th1,098.7423.8 259.3%   
Avg. net profit/employee Rs Th608.2814.9 74.6%   
INCOME DATA
Net Sales Rs m11,04038,915 28.4%  
Other income Rs m2401,134 21.1%   
Total revenues Rs m11,27940,049 28.2%   
Gross profit Rs m1,37612,617 10.9%  
Depreciation Rs m2641,425 18.5%   
Interest Rs m013 0.0%   
Profit before tax Rs m1,35212,313 11.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1700-   
Tax Rs m5833,543 16.4%   
Profit after tax Rs m9398,770 10.7%  
Gross profit margin %12.532.4 38.4%  
Effective tax rate %43.128.8 149.8%   
Net profit margin %8.522.5 37.7%  
BALANCE SHEET DATA
Current assets Rs m7,52345,351 16.6%   
Current liabilities Rs m2,2536,507 34.6%   
Net working cap to sales %47.799.8 47.8%  
Current ratio x3.37.0 47.9%  
Inventory Days Days52127 41.2%  
Debtors Days Days4195 42.6%  
Net fixed assets Rs m1,24021,160 5.9%   
Share capital Rs m166531 31.3%   
"Free" reserves Rs m7,16758,625 12.2%   
Net worth Rs m7,33359,156 12.4%   
Long term debt Rs m00-   
Total assets Rs m9,91267,832 14.6%  
Interest coverage xNM926.8-  
Debt to equity ratio x00-  
Sales to assets ratio x1.10.6 194.1%   
Return on assets %9.512.9 73.2%  
Return on equity %12.814.8 86.4%  
Return on capital %20.820.8 99.6%  
Exports to sales %00-   
Imports to sales %021.8 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA8,485 0.0%   
Fx inflow Rs m1,01532,359 3.1%   
Fx outflow Rs m3,0439,042 33.6%   
Net fx Rs m-2,02823,317 -8.7%   
CASH FLOW
From Operations Rs m5377,759 6.9%  
From Investments Rs m-476-4,783 10.0%  
From Financial Activity Rs m-220-3,142 7.0%  
Net Cashflow Rs m-160-166 96.1%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 51.8 0.0 -  
Indian inst/Mut Fund % 18.2 11.8 154.2%  
FIIs % 1.0 19.0 5.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 17.2 169.2%  
Shareholders   28,591 31,796 89.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare MERCK LTD With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  CADILA HEALTHCARE  NOVARTIS  DR. DATSONS LABS  

Compare MERCK LTD With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 629 Points Higher; Realty and Auto Stocks Witness Buying(Closing)

Indian share markets continued their momentum throughout the day and ended the day on a strong note. Gains were largely seen in the realty sector, telecom sector and auto sector.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (2QFY19); Net Profit Up 92.3% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 92.3% YoY). Sales on the other hand came in at Rs 13 bn (up 44.3% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

MERCK LTD Announces Quarterly Results (2QFY19); Net Profit Up 29.8% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, MERCK LTD has posted a net profit of Rs 411 m (up 29.8% YoY). Sales on the other hand came in at Rs 2 bn (down 27.7% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

MERCK LTD SHARE PRICE


Dec 12, 2018 (Close)

TRACK MERCK LTD

  • Track your investment in MERCK LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE MERCK LTD WITH

MARKET STATS